Company News | News List - Fluoropharm

Company News | News List

FDA Grants Priority Review to Merck’s Supplemental Biologics License Application for KEYTRUDA

FDA Grants Priority Review to Merck’s Supplemental Biologics License Application for KEYTRUDA

Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that the U.S.

READ MORE 2020-12-22

Merck's new HIV drug Pedro (Doravirin) was approved in China

Merck's new HIV drug Pedro (Doravirin) was approved in China

Merck announced recentlythat its new HIV drug Pedro (doravirin tablets) has been officially approved

READ MORE 2020-12-08

FDA Grants Priority Review and EMA Accepts Regulatory Submission for Pfizer’s Abrocitinib, an Oral Once-Daily JAK1 Inhibitor, for Patients 12 and Up with Moderate to Severe Atopic Dermatitis

FDA Grants Priority Review and EMA Accepts Regulatory Submission for Pfizer’s Abrocitinib, an Oral Once-Daily JAK1 Inhibitor, for Patients 12 and Up with Moderate to Severe Atopic Dermatitis

Pfizer announced that the U.S. Food and Drug Administration (FDA) accepted for filing and granted Pr

READ MORE 2020-11-02

ViiV Healthcare receives positive CHMP opinion for long-acting regimen for the treatment of HIV

ViiV Healthcare, the global specialist HIV company majority owned by GSK, with Pfizer Inc. and Shion

READ MORE 2020-10-18

Janssen Announces European Commission Decision for Expanded Use of IMBRUVICA® (ibrutinib) in Combination with Rituximab for Previously Untreated Patients with Chronic Lymphocytic Leukaemia (CLL)

Janssen Announces European Commission Decision for Expanded Use of IMBRUVICA® (ibrutinib) in Combination with Rituximab for Previously Untreated Patients with Chronic Lymphocytic Leukaemia (CLL)

The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that the European Comm

READ MORE 2020-09-09

PIQRAY® is approved and now available in Canada as the first and only treatment specifically for patients with a PIK3CA mutation in HR-positive, HER2-negative advanced breast cancer

PIQRAY® is approved and now available in Canada as the first and only treatment specifically for patients with a PIK3CA mutation in HR-positive, HER2-negative advanced breast cancer

Approval is based on results from SOLAR-1, where PIQRAY®in combination with fulvestrant nearly doubl

READ MORE 2020-08-20

Gastrointestinal stromal tumor (GIST) targeted new drugs! Avapritinib will be approved in the EU in September

Gastrointestinal stromal tumor (GIST) targeted new drugs! Avapritinib will be approved in the EU in September

Blueprint Medicines announced that the European Medicines Agency (EMA) Committee for Medicinal Produ

READ MORE 2020-07-29

Gilead's Veklury has been approved：Veklury is the First Approved Treatment Option for COVID-19 in the European Union

Gilead's Veklury has been approved：Veklury is the First Approved Treatment Option for COVID-19 in the European Union

At present,The COVID-19 epidemic continues to spread rapidly around the world. As of 01am, July 04,

READ MORE 2020-07-05

Announcement on the extension of CPHI North America 2020 in September

Dear Customers,Unfortunately, we have to cancel the plan for our participation in the CPHI North Ame

READ MORE 2020-06-18

New medicine for insomnia! Eisai double-acting orexin receptor antagonist Dayvigo (lemborexant) is launched in the US!

New medicine for insomnia! Eisai double-acting orexin receptor antagonist Dayvigo (lemborexant) is launched in the US!

Japanese pharmaceutical company Eisai recently announced the launch of Dayvigo (lemborexant), a new

READ MORE 2020-06-16

Copyright © 2010-2025 Fluoropharm Co.,Ltd. All rights reserved.

浙ICP备2023037538号-1